Spectral Medical Inc T.EDT

Alternate Symbol(s): EDTXF

Spectral develops devices for unmet medical needs. Sepsis occurs in 1.7M Americans/year causing 250K deaths, often caused by endotoxin. Our devices measure and remove endotoxin from the bloodstream. An FDA confirmatory trial is underway. Dialco, a Spectral sub, offers SAMI, a novel instrument for renal replacement, cleared by FDA. Dialco is seeking FDA approval for DIMI a unique home dialysis enabler. These devices have large commercial potential

TSX:EDT - Post by User

Spectral Medical Inc > 30s a little high Beech.

<< Previous

Bullboard Posts

Next >>

Comment by davikingon Jul 23, 2020 7:09pm

94 Views

Post# 31311202

RE:RE:RE:RE:RE:30s a little high Beech.

SHEESH, MM, you forget who you were posting as AGAIN!!! Were you writing as IG or STT and forgot? If you are writing as MM why don't you just say: " see MY previous revenue post:

mercedesman - (7/23/2020 5:00:40 PM)
RE:RE:RE:RE:30s a little high Beech.

"...and revenue of ~25M. More rev than here either way"

Yes more, especailly when CTSO recognizes grants as current revenue, and Spectral's $ 7M in non refundable payments from Baxter are treated as a Liability (or Deferred Revenue) and not recognized in current revenue except very ssssssssssssssloooooooooowly over a period of 9 years.

Anyway it's more about future revenue and or more precisely the NPV of future cash flows (or at least it should be). Some would say that the annual targeted revenue is $ 1.5 B USD. Others might say $ 6 B CAD$, not including Dialco revenues and or spin off proceeds, EAA revenues (worldwide), etc. (see MM's previous revenue post)

MM

ROTFLAMAOAY

<< Previous

Bullboard Posts

Next >>

Tilray Brands launches health-conscious cannabis drinks